Haoxi Health Technology Limited Announces 1-For-128 Reverse Share Split
Rhea-AI Summary
Haoxi Health Technology (NASDAQ: HAO) approved a 1-for-128 reverse share split of its Class A and Class B ordinary shares. The split becomes effective for trading on Nasdaq on May 21, 2026.
Class A and B par value changes to $0.32. Class A shares outstanding fall from 235,504,007 to about 1,839,876, and Class B from 690,800 to about 5,397, subject to fractional adjustments. No fractional shares will be issued; holdings are rounded up. HAO keeps its Nasdaq symbol with new CUSIP G4290F126.
AI-generated analysis. Not financial advice.
Positive
- No fractional shares; fractional interests are rounded up to whole shares
- Class A shares remain listed on Nasdaq under symbol HAO after the reverse split
Negative
- 1-for-128 reverse split reduces Class A shares from 235,504,007 to about 1,839,876
- 1-for-128 reverse split reduces Class B shares from 690,800 to about 5,397
News Market Reaction – HAO
On the day this news was published, HAO declined 21.35%, reflecting a significant negative market reaction. Argus tracked a peak move of +66.7% during that session. Argus tracked a trough of -50.0% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $995K from the company's valuation, bringing the market cap to $3.66M at that time. Trading volume was exceptionally heavy at 12.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data flags mixed peer action: CHR up, while BAOS and STFS are down. With only 1 peer moving up and 2 down, and sector_momentum marked as non-broad, this looks stock-specific rather than a sector-wide move.
Previous Stock split Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Reverse share split | Negative | -22.4% | Announced 1-for-25 reverse split with large share-count reduction on Nasdaq. |
Prior reverse split on Jan 23, 2025 saw a negative -22.44% 24h reaction, suggesting reverse splits have coincided with pressure on the stock.
Over the past 18 months, Haoxi has already executed a reverse split on Jan 27, 2025, reducing Class A shares from 53.29M to 2.13M and Class B from 17.27M to 0.69M. That move carried a -22.44% next-day reaction. Today’s 1-for-128 reverse split continues that capital-structure adjustment trend, again focusing on share count reduction and trading-price mechanics rather than new operational developments.
Historical Comparison
In the last reverse split on Jan 23, 2025, HAO’s 1-for-25 action led to a -22.44% move. Today’s 1-for-128 reverse split repeats that playbook with an even larger consolidation of share count.
The company progressed from a 1-for-25 reverse split in 2025 to a larger 1-for-128 reverse split in 2026, repeatedly using share consolidations to adjust its capital structure while maintaining the Nasdaq listing framework.
Market Pulse Summary
The stock dropped -21.4% in the session following this news. A negative reaction despite this structural change fits the historical pattern: the prior 1-for-25 reverse split on Jan 23, 2025 corresponded with a -22.44% move. With the stock already trading far below its 1.11 200-day MA and near its 0.0159 52-week low, another reverse split may be viewed as symptomatic of underlying weakness, and past behavior suggests that such actions have not immediately stabilized trading.
Key Terms
par value financial
cusip financial
book-entry form financial
AI-generated analysis. Not financial advice.
BEIJING, May 19, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; “we” or the “Company”), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value
Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on May 21, 2026. Following the reverse share split, the Class A Ordinary Shares and Class B Ordinary Shares will have a new par value of
No fractional shares will be issued in connection with the reverse share split and all such fractional interests will be rounded up to the nearest whole number of Class A Ordinary Shares and Class B Ordinary Shares.
The reverse share split will reduce the number of issued and outstanding Class A Ordinary Shares from 235,504,007 to approximately 1,839,876, and the number of issued and outstanding Class B Ordinary Shares from 690,800 to approximately 5,397, subject to any adjustments resulting from the treatment of the fractional shares.
On March 24, 2026, the board of directors of the Company approved the reverse share split of the Class A Ordinary Shares and Class B Ordinary Shares, at a ratio of 1-for-128.
Transhare Corporation LLC is acting as the exchange agent and paying agent for the reverse share split. Shareholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse share split.
Transhare Corporation LLC will provide instructions to any shareholders with certificates regarding the process in connection with the exchange of pre-reverse share split share certificates for ownership in book-entry form or share certificates on a post-reverse share split basis. Shareholders are encouraged to contact their bank, broker or custodian with any procedural questions.
About Haoxi Health Technology Limited
Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company’s growth is driven by the rise of news feed ads and the rapid development of the healthcare section. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, Wechat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information on our latest innovations and developments, visit http://ir.haoximedia.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; the Company's future acquisition opportunities; the Company's ability to identify any acquisition opportunities that fit with our business strategies; the Company's ability to consummate an attractive acquisition and realize the benefits of such transaction; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Haoxi Health Technology Ltd
Investor Relations
ir@haoximedia.com
